product line
MISSION®
form
lyophilized powder
description
Powered by Eupheria Biotech
esiRNA cDNA target sequence
CAGCTGGGATCATGTTGTTGGCCCTGGTCTGTCTGCTCAGCTGCCTGCTACCCTCCAGTGAGGCCAAGCTCTACGGTCGTTGTGAACTGGCCAGAGTGCTACATGACTTCGGGCTGGACGGATACCGGGGATACAGCCTGGCTGACTGGGTCTGCCTTGCTTATTTCACAAGCGGTTTCAACGCAGCTGCTTTGGACTACGAGGCTGATGGGAGCACCAACAACGGGATCTTCCAGATCAACAGCCGGAGGTGGTGCAGCAACCTCACCCCGAACGTCCCCAACGTGTGCCGGATGTACTGCTCAGATTTGTTGAATCCTAATCTCAAGGATACCGTTATCTGTGCCATGAAGATAACCCAAGAGCCTCAGGGTCTGGGTTACTGGGAGGCCTGGAGGCATCACTGCCAGGGAAAAGACCTCACTGAATGGGTGG
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
General description
MISSION® shRNA是核糖核酸内切酶制备的siRNA。它们是靶向相同mRNA序列的siRNA异质混合物。这些多重沉默触发（multiple silencing trigger）导致高度特异性的、有效的基因沉默。
如需其他详细信息并查看所有可用的esiRNA选项，请访问SigmaAldrich.com/esiRNA。
如需其他详细信息并查看所有可用的esiRNA选项，请访问SigmaAldrich.com/esiRNA。
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
Sara Yousef et al.
Journal of translational medicine, 13, 197-197 (2015-06-20)
Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients' bone marrow (BM) and immunotherapeutic approaches could contribute to
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持